1Grant MB ,Boulton ME ,Ljubimov AV. Erythropoietin: when liability becomes asset in neurovascular repair [J].J Clin Invest,2008,118(2):467.
2Imamura R, Isaka Y, Iehimaru N, et al. Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimu- lating erythropoiesis[J].Biochem Biophys Res Commun, 2007,353(3) : 786.
3Rosenzweig MQ ,Bender CM ,Lucke JP,et al. The decision to prema- turely terminate a trial of R-HuEPO due to thrombotic events[J].J Pain Symptom Manage, 2004,27(2) : 185.
4Leist M, Ghezzi P, Grasso G, et al.Derivatives of erythropoietin that are tissue protective but not erythropoietic [J].Science,2004,305 (5681) :239.
5Fiordaliso F, Chimenti S,Staszewsky L,et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia- reperfusion injury[J].Proc Natl Acad Sci USA ,2005,102(6):2046.
6Moon C ,Krawczyk M ,Paik D ,et al.Erythropoietin,modified to not stimulate red blood cell production, retains its cardioprotective prop- erties [J]. J Pharmacol Exp Ther, 2006,316(3): 999.
7Chin H, Wakao H, Miyajima A, et al. Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor beta subunit (betalL3) and recruitment of Star5 to possible StatS-docking sites in betaIL3[J]. Blood, 1997,89(12) :4327.
8Parsa C J, Kim J, Riel RU, et al.Cardioprotective effects of erythropoi- etin in the reperfused ischemic heart: a potential role for cardiac fi- broblasts[J].J Biol Chem,2004,279(20):20655.
9Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythro- poietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling[J].Proc Natl Acad Sci USA,2003 100(8) :4802.
10Parsa CJ,Matsumoto A, Kim J,et al. A novel Protective effect of erythropoietin in the infarcted heart [J].J Clin Invest ,2003,112(7):999.
